Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial

Phase 3RecruitingNCT05211375

Seoul National University Bundang Hospital130 enrolled

Overview

In this study, the effects of SG with DJB and SG alone for the treatment of type 2 diabetes mellitus (T2DM) will be compared in patients other than the two groups at both extremes who are expected to show excellent effects of metabolic surgery with SG alone (mild T2DM) and who need SG with DJB (severe T2DM). This study is to target patients with poor blood sugar control despite current medical treatment, although the beta-cell function of the pancreas is preserved. Therefore, this study is aimed at patients who have been using insulin for less than 10 years with T2DM, or taking diabetic medications with HbA1c ≥ 7.0% for less than 10 years with T2DM. The investigators hypothesize that the treatment effects of SG with DJB for T2DM will be superior to that of SG in this group

Most Asian patients undergoing metabolic surgery for the treatment of T2DM have BMI as low as 30-35 kg/m2. If SG is performed for the treatment of T2DM in these patients, weight may decrease after the surgery; however, T2DM may recur after 6 months to 1 year. Therefore, it is difficult to find clinical studies on SG for metabolic surgery in Asians, and gastric bypass may be more appropriate as metabolic surgery. However, gastroscopy for the remnant stomach after gastric bypass is practically impossible. Therefore, gastric bypass may be a fatal drawback for East Asian patients with a high incidence of gastric cancer. In recent years, modified duodenal switch (SG with duodenojejunal bypass \[DJB\], which is defined as the procedure that makes jejunal bypass shorter than the traditional duodenal switch) is often performed as metabolic surgery, and studies on this surgical technique are being actively conducted in Japan. SG with DJB has both effects of stomach restriction and foregut bypass. However, SG with DJB is more disadvantageous compared to SG alone in nutrient absorption after surgery. This is a natural result of bypassing the duodenum and proximal jejunum. Therefore, SG with DJB should not be performed when it is unnecessary, and it should be performed in patients who are expected to show significant improvement in T2DM. However, there is no existing guideline on which patients can receive SG with DJB or SG alone, and there are also no clinical studies on these aspects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

Interventions

Duodenojejunal bypassPROCEDURE

Sleeve gastrectomy will be performed in the same manner as in the SG group. DJB will be performed by transection of the duodenum and bypassing 250 cm of the proximal jejunum. The handsewn suture will be used for duodenojejunal anastomosis, and the size of anastomosis will be 1.5 - 2 cm. Single anastomosis will be performed rather than Roux-en-Y fashion.

Sleeve gastrectomyPROCEDURE

Sleeve gastrectomy will be performed using 36-38 Fr bougie. The initial stapling start point will be between 4-6 cm from the pylorus, and the last stapling will be performed at least 1 cm away from His angle. The height of the automatic stapler will be selected based on the researcher's discretion.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age over 18 years * BMI equal to or greater than 27.5 kg/m2 * T2DM duration ≤ 10 years * Using insulin, or HbA1c ≥ 7.0% while taking diabetes medication * C-peptide level higher than 1.0 ng/mL * Presence of type 2 diabetes fulfilling the following criteria * Consent to not become pregnant for at least 1 year after surgery * Willingness to provide voluntary informed consent Exclusion Criteria: * Presence of uncontrolled severe gastroesophageal reflux (LA classification C or more in esophagogastroduodenoscopy) * History of previous metabolic surgery for T2DM * History of gastrointestinal surgery, such as gastrectomy or anti-reflux surgery, which may affect the result of metabolic surgery * Therapy regimen of more than 3 psychiatric drugs owing to poorly controlled psychiatric disorders * Suicidal attempts within the last 12 months * Treatment for alcohol and drug abuse within the last 12 months * Vulnerability factors (lacking mental capacity, pregnancy or planning of pregnancy, lactation) * Unsuitability as per the discretion of the researcher

Outcomes

Primary Outcomes

Complete remission rate of type 2 diabetes

HbA1c \<6% (or fasting blood glucose \[FBG\] \<100 mg/dL) without using any diabetes medication

Time frame: 5 years after surgery

Secondary Outcomes

Complete remission rate of type 2 diabetes

HbA1c \<6% (or fasting blood glucose \[FBG\] \<100 mg/dL) without using any diabetes medication

Time frame: 1, 3, 10 years after surgery

Partial remission rate of type 2 diabetes

Definition of partial remission of diabetes: HbA1c of 6-6.4% (or FBG of 100-125 mg/dL) without using any diabetes medication